🧾 What This Document Is

This is a Form 8-K, a required report companies file with the SEC to announce major, material events that shareholders should know about. Think of it as a "breaking news" alert for investors. This specific 8-K from Climb Bio, Inc. (CLYM) is reporting a change in a key financial executive.

🏢 What The Company Does

👉 In simple terms, Climb Bio is a clinical-stage biotechnology company. They are in the business of discovering and developing new drugs, but none have been approved for sale yet. Being "clinical-stage" means their products are still being tested in people (in clinical trials) and are not on the market. Their stock trades on the Nasdaq under the ticker CLYM.

🚨 The Main Event: Leadership Shakeup

The entire filing is about one important change in the company's financial leadership, effective April 30, 2026.

• Who's Leaving: Cindy Driscoll, the Senior Vice President, Finance and principal accounting officer.
• How: The departure was a mutual agreement between her and the company.
• Who's Taking Over: Dr. Susan Altschuller, the current Chief Financial Officer (CFO), will add the role of principal accounting officer to her responsibilities.

👉 Why it matters: The principal accounting officer is crucial for ensuring the company's financial books are accurate. A transition here is a notable event for investors to monitor.

👤 Meet The New Top Accountant

Dr. Susan Altschuller (age 44) is stepping into the expanded role. Her resume is packed with CFO experience at other biotech companies, which is a good sign of expertise.

• Most Recent: CFO at Dragonfly Therapeutics (private) in 2024.
• Before That: CFO at Cerevel Therapeutics until it was bought by AbbVie in 2024.
• Also: CFO at ImmunoGen (2020-2023) and held finance roles at Alexion Pharmaceuticals.
• Education: Impressive credentials with a Ph.D. in biomedical engineering and an MBA from MIT Sloan.

The filing confirms she has no family ties to other executives and no conflicts of interest. Her compensation package did not change with this new title.

📅 Key Dates to Remember

• April 1, 2026: The mutual agreement for the separation was reached.
• April 30, 2026: This is the Separation Date. Cindy Driscoll officially leaves, and Dr. Altschuller officially becomes the principal accounting officer.

🔮 What This Signals & Why It Matters

For a young, clinical-stage biotech like Climb Bio, stability and expertise in the finance function are critical. They burn cash to fund research and need to communicate clearly with investors.

• 👍 Positive Signal: Promoting an experienced CFO from within suggests a smooth transition. Dr. Altschuller's deep background in biotech finance is a strength.
• ⚠️ Thing to Watch: Any leadership change creates a small risk. Investors will watch the company's financial reporting and communication in the coming quarters to ensure everything runs smoothly.

⚖️ Big Picture: Strengths & Risks

• 👍 Strength: The company is managed by an experienced executive team, especially in the finance department with Dr. Altschuller.
• ⚠️ Risk: As a clinical-stage company, Climb Bio's success depends almost entirely on whether its drug candidates work in trials and get approved. This executive change is a secondary, but important, operational factor.

🧠 The Analogy

Changing your CFO/Principal Accounting officer is like a sports team changing its head coach and general manager right before the playoffs. The new person might be incredibly qualified (the star assistant coach), but you'll be watching closely to see how the team adapts the game plan without missing a beat.

📇 Key Contacts & People

• Aoife Brennan, M.B., Ch.B. - President and Chief Executive Officer (signed the report)
• Cindy Driscoll - Senior Vice President, Finance (departing)
• Dr. Susan Altschuller, Ph.D., MBA - Chief Financial Officer, soon-to-be Principal Accounting Officer
• Registrant Contact: Climb Bio, Inc., 20 William Street, Suite 145, Wellesley Hills, Massachusetts 02481. Phone: (866) 857-2596.

🧩 Final Takeaway

Climb Bio is undergoing a routine but important change in its financial leadership team. The departure of the SVP of Finance is being smoothly handled by expanding the responsibilities of their experienced CFO, Dr. Susan Altschuller. For investors, this is about maintaining operational continuity while the company focuses on its core mission of developing new drugs.